|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Discussion & conclusion:</b> These data indicate MCCC2 overexpression predicts an unfavorable prognosis and promotes cell proliferation in breast cancer, which may serve as a potential prognostic biomarker.
|
30895811 |
2019 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry analysis revealed that MCCC2 overexpression was significantly associated with Tumor, Node, Metastasis stage and lymph node metastasis and predicted an unfavorable prognosis (p < 0.05).
|
30895811 |
2019 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Discussion & conclusion:</b> These data indicate MCCC2 overexpression predicts an unfavorable prognosis and promotes cell proliferation in breast cancer, which may serve as a potential prognostic biomarker.
|
30895811 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry analysis revealed that MCCC2 overexpression was significantly associated with Tumor, Node, Metastasis stage and lymph node metastasis and predicted an unfavorable prognosis (p < 0.05).
|
30895811 |
2019 |
|
Drug abuse
|
0.010 |
Biomarker
|
group |
BEFREE |
For the MCCB domains displaying significant (p < 0.05) correlations, within group hierarchical linear regression, was done to assess whether abuse and neglect were significant predictors of cognition after controlling for the effect of education.
|
29268811 |
2018 |
|
Schizoaffective Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, in the schizophrenia-schizoaffective disorder group, after controlling for demographic characteristics in stepwise multiple regression analyses, MSCEIT-ME was the only significant predictor of the QLS total score and the QLS interpersonal relations and intrapsychic foundations subscales, with none of the MCCB factors entering any of the regression models.
|
29486955 |
2018 |
|
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
N2 amplitude was not correlated with psychopathological dimensions or MCCB-assessed cognitive deficits in SCZ.
|
29243531 |
2018 |
|
Chronic schizophrenia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
People diagnosed with chronic schizophrenia (n = 821) were assessed with the MCCB and PANSS, and rated by high contact informants with SLOF.
|
30029051 |
2018 |
|
Discomfort
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Multivariate analysis of variance and univariate analysis of variance revealed participants with intact ER had better neurocognition (MATRICS Consensus Cognitive Battery [MCCB]), metacognition (Metacognition Assessment Scale-Abbreviated), ToM (The Hinting Task), and higher emotional discomfort symptoms than participants with impaired scores.
|
30439777 |
2018 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
After screening marine actinomycetes isolated from sediment samples collected from the Arctic fjord Kongsfjorden for potential anticancer activity, an isolate identified as Streptomyces artemisiae MCCB 248 exhibited promising results against the NCI-H460 human lung cancer cell line.
|
28401470 |
2017 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
After screening marine actinomycetes isolated from sediment samples collected from the Arctic fjord Kongsfjorden for potential anticancer activity, an isolate identified as Streptomyces artemisiae MCCB 248 exhibited promising results against the NCI-H460 human lung cancer cell line.
|
28401470 |
2017 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
After screening marine actinomycetes isolated from sediment samples collected from the Arctic fjord Kongsfjorden for potential anticancer activity, an isolate identified as Streptomyces artemisiae MCCB 248 exhibited promising results against the NCI-H460 human lung cancer cell line.
|
28401470 |
2017 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ENDOD1 and ACSL3 showed down-regulation in high-grade and metastatic PCa, while MCCC2 was overexpressed in low-grade PCa.
|
21829708 |
2011 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ENDOD1 and ACSL3 showed down-regulation in high-grade and metastatic PCa, while MCCC2 was overexpressed in low-grade PCa.
|
21829708 |
2011 |
|
Peroxisome Biogenesis Disorder, Complementation Group 7
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Two MCCB missense mutations and one splicing defect mutation leading to early MCC beta truncation were found in CGB patients.
|
11170888 |
2001 |
|
Methylcrotonyl-CoA carboxylase deficiency
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
A single mutation in MCCC1 or MCCC2 as a potential cause of positive screening for 3-methylcrotonyl-CoA carboxylase deficiency.
|
22264772 |
2012 |
|
Methylcrotonyl-CoA carboxylase deficiency
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Newborn screening for 3-methylcrotonyl-CoA carboxylase deficiency: population heterogeneity of MCCA and MCCB mutations and impact on risk assessment.
|
16835865 |
2006 |
|
Myocardial Infarction
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations.
|
21211798 |
2011 |
|
Alopecia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Comatose
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Failure to Thrive
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Ketosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Lethargy
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Movement Disorders
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|